W. Neunteufel

Squamous Cell Carcinoma (SCC) Antigen in Patients with Invasive Cervical Carcinoma during Primary Irradiation

In a prospective study, serum concentrations of squamous cell carcinoma (SCC) antigen were determined by radioimmunoassay from 74 healthy volunteers and 54 patients with cervical carcinoma who underwent irradiation therapy. 5.4% of the controls had SCC levels greater than 3.0 ng/ml, which was considered as upper limit of the normal range. 31/54 (57.4%) patients and 60% of the patients with SCC had elevated pretreatment levels. In all patients with pretreatment serum levels above 3.0 ng/ml, SCC serum levels decreased during irradiation therapy. 4/5 patients with posttreatment levels greater than 0.5 ng/ml developed recurrence or persistence of tumor, 1 patient could not be followed up. Good conformity was found between SCC antigen serum levels and therapy response. SCC antigen determinations during and after therapy provide a useful tool in detecting progression and persistence of tumor.

Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls

SummarySquamous cell carcinoma antigen levels in 74 healthy volunteers, 57 patients with CIN and 91 patients with cervical carcinoma were determined by radioimmunoassay. 5.4% of healthy volunteers were above and all patients with CIN were below 3.0 ng/ml. 63.1% of 65 patients with primary squamous cell carcinoma, 1 out of 7 adenocarcinomas and 68.4% of 19 patients with recurrence of squamous cell carcinoma of the cervix had elevated SCC antigen levels. Elevated posttreatment levels carried a high risk factor of tumor persistence. Increases in SCC antigen levels during follow up usually signified recurrent carcinoma.

CA19-9, CA125 and CEA in Endometrial Carcinoma Tissue and Its Relation to Hormone Receptor Content and Histological Grading -

SummarySamples of 40 endometrial carcinomas were examined by immunohistochemical methods for CA19-9, CA125 and CEA. CA19-9 was detected in 93%, CA125 in 65% and CEA in 58%. CA19-9 was detected in more than 50% of tumor cells in 14 cases and the same was true for CA125 in six cases. In no tumor was CEA found in more than half the cells. The distribution of CA125 and CEA was markedly more heterogenous than that of CA19-9. There was no statistically significant correlation between immunohistochemical markers on the one hand, and estrogen and progesterone receptor content on the other. A correlation between histological grading and marker detection was only found for CA19-9. CA19-9 was detected in almost all endometrial carcinoma samples, and was the most homogenously distributed. This makes CA19-9 a possibly useful tumor marker for endometrial carcinoma.

The significance of determining CA 15-3 in the cytosol of breast cancer

SummaryThe identification of tumor markers in patients who had undergone operation for breast cancer provides important information in the follow-up in addition to evaluation by clinical and visual methods. The aim of our study was to determine the clinical prospective value of CA 15-3, mucin-like carcinoma-associated antigen and carcinoembrynic antigen in preoperative measurement of serum samples in patients with primary breast cancer, and to determine CA 15-3 and steroid receptors in the cytosol of the tumor. The results show that the most exact correlation occurred between serum CA 15-3 and the different stages of the tumor. However, there is no conclusive evidence for the prognosis and the course of the disease from preoperative findings of tumor markers in serum samples or in the cytosol of the tumor in patients with breast cancer.

MCA, ein neuer Tumormarker für Nachsorgeuntersuchungen bei Mammakarzinompatienten

MCA (“mucin-like carcinoma-associated antigen”) kann mit einem Enzymimmunoassay von Hoffmann La Roche in verschiedenen Korperflussigkeiten wie Serum, Harn, Ascites, Fruchtwasser oder Muttermilch gemessen werden. Wir haben einige Eigenschaften von MCA untersucht und die Wertigkeit dieses neuen Markers mit den bereits etablierten Markern CA15-3 (Centocor) und CEA (Serono) bei beschwerdefreien Mammakarzinompatienten mit einem erhohten Ruckfallrisiko verglichen. Als obere Konzentrationsgrenzen fanden wir bei einem Kollektiv von gesunden Frauen fur MCA14 E/ml, fur CA15-3 27 E/ml und fur CEA 3 ng/ml Serum.

Die Wertigkeit von SCC als Marker beim Zervixkarzinom

Im Gegensatz zur Vorsorge kann die Verlaufskontrolle von Zervixkarzinompatientinnen problematisch sein. Obwohl bereits seit 1973 uber Tumorantigene des Zervixkarzinoms berichtet wurde, gelang es erst Kato et al. 1977 mit dem Tumorantigen TA-4 aus Plattenepithelkarzinomen der Cervix uteri einen brauchbaren Tumormarker zu isolieren.

CA 125 am Gewebsschnitt von Ovarialtumoren und im Serum

Paraffinschnitte formolfixierter Gewebsproben von 102 Ovarialtumoren wurden mit dem monoklonalen Antik6rper OC 125 40 min, mit Biotin-konjuiertem Horse-anti-mouse-IgG 10 rain und mit einem Avidin-PeroxidaseKomplex ebenfalls 10 rain inkubiert. Mit 3-Amino-9-~_thyl-Karbazol wurde die F~irbung entwickelt und mit Hfimatoxylin gegengef~rbt. Bei 29 Patienten aus diesem Kollektiv wurden 1 -5 Tage vor der Tumorexstirpation Serum aus dem peripheren Blut gewonnen und mit einem Immunradiometrischen Assay der CA 125-Spiegel gemessen (Grenzwert 35 U/ml). 17 der 29 Operationsprfiparate waren Karzinome, 5 Borderline-Tumoren und 7 benigne Ovarialtumoren.